Q1 2026 · 13F-HR
ACORN CAPITAL ADVISORS, LLCholdings as filed
Filed 2026-05-15 · accession 0001636587-26-000029
$351.8M
Reported value
22
Positions
2026-03-31
Period end
The Brief · ACORN CAPITAL ADVISORS, LLC · Q1 2026
AI · grounded in 13F
ACORN CAPITAL ADVISORS, LLC established a new position in JBIO valued at $11.05M. The fund also initiated a new stake in KPTI for $1.6M and increased its holdings in CADL by 35.55%. Conversely, the fund closed its entire position in ACRV, resulting in a $976,622 reduction.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 880881107 | 430 | TERNS PHARMACEUTICALS INC | $92.1M | 26.2% | 1,746,264 | Common | SOLE |
| 156944100 | CGON | CG ONCOLOGY INC | $76.6M | 21.8% | 1,130,501 | Common | SOLE |
| M96088105 | URGN | UROGEN PHARMA LTD | $30.1M | 8.55% | 1,673,420 | Common | SOLE |
| 74587V107 | PBYI | PUMA BIOTECHNOLOGY INC | $26.4M | 7.50% | 4,131,299 | Common | SOLE |
| 89532M101 | TRVI | TREVI THERAPEUTICS INC | $25.6M | 7.27% | 2,144,844 | Common | SOLE |
| 137404109 | CADL | CANDEL THERAPEUTICS INC | $17.2M | 4.89% | 3,497,948 | Common | SOLE |
| 055477103 | BCAX | BICARA THERAPEUTICS | $12.8M | 3.64% | 643,382 | Common | SOLE |
| 68277Q105 | OKUR | ONKURE THERAPEUTICS INC | $11.8M | 3.34% | 2,839,674 | Common | SOLE |
| 008064206 | JBIO | JADE BIOSCEINCES INC | $11.1M | 3.14% | 786,760 | Common | SOLE |
| 74365U107 | TARA | PROTARA THERAPEUTICS INC | $9.1M | 2.59% | 1,752,115 | Common | SOLE |
| 92337C203 | VSTM | VERASTEM INC | $7.8M | 2.21% | 1,469,153 | Common | SOLE |
| 23256X407 | HELP | HELUS PHARMA INC. | $7.4M | 2.10% | 1,540,266 | Common | SOLE |
| 04746L203 | LONA | LEONABIO, INC. | $6.5M | 1.85% | 634,539 | Common | SOLE |
| 05153U107 | AURA | AURA BIOSCIENCES INC | $4.0M | 1.13% | 595,744 | Common | SOLE |
| 00032Q104 | WHWK | WHITEHAWK THERAPEUTICS INC | $3.9M | 1.12% | 1,139,363 | Common | SOLE |
| 14147L108 | CRDF | CARDIF ONCOLOGY INC | $2.9M | 0.81% | 1,762,084 | Common | SOLE |
| 746964105 | QTTB | Q32 BIO INC. | $2.0M | 0.57% | 315,052 | Common | SOLE |
| 48576U205 | KPTI | KARYOPHARM THERAPEUTICS INC | $1.6M | 0.46% | 287,826 | Common | SOLE |
| 471871202 | JSPR | JASPER THERAPEUTICS | $1.2M | 0.35% | 1,411,492 | Common | SOLE |
| 98420X103 | ASNSUSD | X4 PHARMACEUTICALS INC | $966,583 | 0.27% | 234,039 | Common | SOLE |
| 09077B104 | BCABGBP | BIOATLA INC | $865,015 | 0.25% | 5,406,345 | Common | SOLE |
| 92941V308 | VYNE | VYNE THERAPEUTICS INC | $855 | 0.00% | 1,425 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.